microdose glp 1 for menopause GLP-1 Microdosing Perimenopause: Benefits & Risks How microdosing GLP-1 drugs became
Description
Patent protection prevents generic manufacturers from producing lower-cost versions until exclusivity periods expire
The SURMOUNT-OSA trials showed that tirzepatide reduced the apnea-hypopnea index (AHI) by approximately 55-63% and body weight by 18-20%
About this article Cite this article Naude, J., Zentner, A., Suresh, P
10.1016/j.cct.2024.107692 5 CortesT
